Breaking AI & Tech News Analyzed

Wegovy Weight-Loss Pills Get UK Approval Patients in the UK will soon have access to buy Wegovy, a weight-loss pill approved by the Medicines and Healthcare products Regulatory Agency (MHRA). This pill is the first GLP-1 receptor agonist tablet for weight loss to be approved in the UK, making it the third country to authorize it, following the US and the United Arab Emirates. Key Details of Wegovy Wegovy pills contain semaglutide and are approved for adults with obesity (BMI of 30 or higher) or those who are overweight (BMI of 27-30) with at least one weight-related health condition. Clinical trials showed that patients on the highest dose lost 14-17% of their body weight after 64 weeks. Availability and Pricing Until Wegovy tablets are approved by the National Institute for Health and Care Excellence, they will not be available on the NHS. Eligible patients will need to obtain a private prescription. Prices have not been agreed yet, but patients hope they will be cheaper than injections, which typically cost £90-£300 a month. Administration and Side Effects Patients will start on 1.5mg, with doses increasing to 4mg, 9mg, and 25mg, with at least one month at each level. Common side effects include gastrointestinal disorders such as nausea, diarrhea, constipation, and vomiting. Patients are advised to report any side effects to their doctor or the yellow card scheme. Expert Reactions Experts have welcomed the approval, citing the need for additional treatment options for sustained weight loss. Professor Naveed Sattar noted that expanding effective treatments is crucial in helping people reduce caloric intakes in an obesogenic environment. Jason Murphy, head of pharmacy at Chemist4U, described the announcement as a 'major step forward' in treating obesity. Future Outlook With an estimated 2.5 million people using weight-loss injections in the UK, demand for weight-loss pills is expected to be high. However, concerns have been raised about the potential for counterfeit weight-loss treatments in the black market.

The Lead A new study reveals that apitegromab, a drug promoting muscle growth, could significantly reduce the loss of lean body mass when using popular weight-loss medications like tirzepatide (found in Mounjaro). This breakthrough addresses a significant concern with current weight-loss treatments that cause patients to lose muscle along with fat. The Scientific Breakthrough GLP-1 based weight-loss jabs such as Wegovy and Mounjaro have proven highly effective for people who are overweight or obese, but studies show 25-40% of total weight loss comes from reduction in lean body mass – non-fat components including muscle. This matters because lean body mass is important for physical strength, burns more calories than fat tissue, and is linked to a lower risk of type 2 diabetes. Apitegromab works by blocking myostatin, a protein involved in inhibiting muscle growth. In a small trial, researchers in the US randomly divided 102 participants into two groups: 51 received apitegromab alongside tirzepatide, while the other 51 received a placebo with tirzepatide. The Clinical Trial Results After 24 weeks, the trial revealed that total weight loss was similar between the two groups. However, participants given apitegromab alongside tirzepatide lost on average 1.6kg (3.5lb) of lean mass (14.6% of total weight loss), while those given tirzepatide with a placebo lost an average of 3.5kg of lean mass. This means apitegromab was associated with a 55% greater retention of lean mass relative to placebo. The study had limitations, including that most participants were women and the trial was small and short in duration. However, the number of people experiencing side-effects was similar between the two groups, with most deemed to be mild. The Implications for Weight Loss Treatment Prof Alexander Miras, an obesity expert at Ulster University not involved in the work, described the findings as very important. While GLP-1s have been associated with improved "functionality" – making everyday activities easier – they've also been linked to loss in muscle mass and strength. This new medication may help reduce these effects and improve functionality even further. Prof Naveed Sattar, a cardiometabolic medicine expert at the University of Glasgow, emphasized that larger-scale and longer trials are needed to confirm safety and actual health benefits. In the meantime, he recommended that people prescribed weight-loss drugs should be supported to increase physical activity, which can help maintain muscle mass in a physiological way. The Future of Weight Loss Therapies The findings suggest a promising direction for weight-loss treatments that preserve muscle mass while reducing fat. As the popularity of GLP-1 based medications continues to grow, addressing muscle loss could become an important focus for pharmaceutical companies and healthcare providers. Future research will need to confirm the long-term safety and effectiveness of combining apitegromab with weight-loss medications. If successful, such combinations could become standard practice, potentially improving patient outcomes and quality of life during weight loss journeys.

The Global Obesity Landscape: Not a Uniform EpidemicA continuing rise in obesity around the world is not inevitable, research suggests, with rates in some countries levelling off or potentially in decline. Researchers say focusing on what has been described as a global epidemic of obesity hides large variations in trends across different countries, sexes and age groups.Majid Ezzati, a professor of global environmental health at Imperial College London and author of the study, said: "I think the thing that's really important is this diversity exists even across countries that have really similar economic, environmental, technological features. So countries may look the same on the surface of it but obesity looks different."Comprehensive Analysis Reveals Complex PatternsWriting in the journal Nature, the international team, which involved a network of almost 2,000 researchers, described how for each country they calculated the change in the prevalence of obesity each year between 1980 and 2024. They drew on data from 4,050 population-based studies involving 232 million participants aged five years and above.They found that the prevalence of obesity increased in almost all countries over the 45-year period. However, in most high-income countries, a rapid rise in the prevalence of obesity has been replaced by a slower increase, a plateau, or a potential decline.Regional Variations in Obesity PrevalenceThe rate of growth in obesity is slowing in adults in the US and UK, reaching a prevalence of 40-43% and 27-30% respectively in 2024. Obesity is increasing steadily in Finland, has plateaued in Germany and may have started to decline in France, where 24-25%, 20-23% and 11-12% of adults respectively were thought to have the condition in 2024.Slowdowns were often seen in children and adolescents before adults. For the former group, the slowdown started as early as 1990 in Denmark and rates stabilised in most high-income countries by the mid-2000s. Obesity has plateaued in boys and girls in the UK, US, Germany and Japan at prevalences of 10-12%, 20-23%, 7-12% and 3-7% respectively.Meanwhile, obesity among young people and adults in many low-income and middle-income countries continues to rise and in some cases this is accelerating.Understanding the Drivers Behind Divergent TrendsThe team say it is important now to unpick what is behind the trends in different countries. The situation is complex: while there may be shared reasons for obesity, such easy access to unhealthy foods or a decrease in physical activity, the team say country-specific factors rooted in social, economic and policy considerations could also be important, from perceptions around body image to the presence or absence of interventions such as healthy school meals.Naveed Sattar, a professor of metabolic medicine at the University of Glasgow, who was not involved in the work, said the study highlighted how obesity trends were diverging sharply across countries. "English-speaking nations are doing particularly poorly, with the UK now among the countries with the highest obesity levels worldwide," he said.Sattar said it was encouraging that some countries appeared to have reached a plateau in obesity rates. "Understanding what has worked in those settings is crucial as it could help shape more effective public health strategies for the UK," he said, although he noted there could be country-specific aspects or customs at play.Future Outlook and Potential InterventionsHe said the rapid rise in obesity across many developing countries was especially concerning, not least as it could result in increases in diabetes and cardiovascular conditions.He added: "Looking ahead, it will be important to see how wider use of effective weight-loss medicines affects obesity trends, particularly in the UK and the United States. Recent signs of stabilisation in the USA suggest there may be room for cautious optimism. Combining evidence-based medicines with strong public health measures could begin to shift obesity rates in the right direction."

The New Tool for Obesity-Related Disease Risk A new tool developed by UK researchers can help identify individuals most at risk of obesity-related diseases, such as type 2 diabetes, gout, and stroke. This tool uses a type of AI called interpretable machine learning to analyze data from nearly 200,000 participants of the UK Biobank project. How the Tool Works The researchers applied the AI tool to data from participants with a BMI of 27 or greater, identifying 20 health, lifestyle, and demographic features that could predict the 10-year risk of 18 different obesity-related complications. These features include age, sex, total cholesterol, and creatinine levels. The Data Analysis The team tested the validity of the tool, dubbed Obscore, using UK Biobank data and datasets from two independent health studies. The results showed that participants with the same age, sex, and BMI can have very different risks for various obesity-related conditions. The Impact Analysis The tool could help inform strategies for prioritizing who should receive weight-loss interventions, particularly in cases where access to NHS treatments is limited. According to Prof Nick Wareham, the tool is not about extending the use of particular therapies, but rather about developing and validating a score that can help with more rational resource allocation. The Prediction The researchers believe that their tool could be useful for prioritizing individuals who would benefit most from weight-loss medications. However, Naveed Sattar, a professor of cardiometabolic medicine at the University of Glasgow, noted that substantial further development and validation will be required before such an approach can be translated into routine clinical practice.

Researchers have made a significant breakthrough in understanding why weight-loss medications, such as GLP1 receptor agonists, work better for some individuals than others. A recent study published in Nature has identified genetic variations in two genes involved in gut hormone pathways that regulate appetite and digestion. These genetic variations may help account for different weight-loss results or side-effects when taking glucagon-like peptide 1 (GLP1) medicines, which mimic natural gut hormones to regulate appetite, insulin release, and digestion. The study analyzed data from 27,885 patients on GLP1 drugs and found that specific genetic variants were associated with slightly more weight loss or side-effects like nausea and vomiting. The findings suggest that genetic differences may contribute to why people respond differently to weight-loss jabs. However, the overall impact of genetics appeared to be modest, with non-genetic factors such as sex, drug type, dose, and duration appearing to explain a substantially larger proportion of variability. The study's results reinforce that while there is substantial variability in response to GLP1 therapies, genetics is only one part of a much more complex picture. According to Marie Spreckley, an obesity expert at the University of Cambridge, the study provides plausible evidence that genetic variants could affect outcomes. However, she notes that the magnitude of these genetic effects is small in clinical terms, and that behavioral, clinical, and treatment-related factors remain the dominant drivers of outcomes. The study's authors suggest that their findings could support future efforts to use genetic information when making treatment choices for obesity. However, Spreckley cautions that the evidence is not yet sufficient to support using genetic information to guide treatment decisions in routine clinical practice.

The peptide-testing industry has seen a significant surge in demand, with laboratories testing thousands of unregulated substances claiming to support weight-loss and wellness. This growth is largely driven by the injectable peptide craze, with experts warning about the lack of reliable safety data and quality control.Peptides are short chains of amino acids, which can be found naturally in the body or made synthetically in laboratories. They include active ingredients in prescription weight-loss drugs, such as Wegovy, as well as experimental compounds pushed online by the booming biohacking and anti-ageing industries.Laboratories, such as Finnrick in Texas, have reported a substantial increase in testing requests, with around 60,000 samples processed annually, including roughly 2,000 orders from the UK since 2024. About a third of the products analysed failed basic quality checks, with issues including incorrect identity, purity, and quantity.Experts, including Dr. Luke Turnock and Peter Magic, have highlighted the risks associated with these unregulated substances, including potential long-term harms such as increased cancer risk and damage to organs. The large profit margins have also drawn nefarious actors into the supply chain.The UK is a significant market for peptides, with 2,000 testing orders since 2024, tied with Canada for third place globally. The Royal Pharmaceutical Society's Prof Amira Guirguis emphasized the need for oversight, traceability, and quality assurance in the peptide market.

Eli Lilly, the US pharmaceutical group behind the Mounjaro weight-loss drug, is seeking to resume its investments in the UK after pausing them last year. The company is in talks with UK ministers to regularly increase NHS drug prices and end a rebate scheme. Patrik Jonsson, president of Eli Lilly's international business, expressed optimism about reaching an agreement this summer.The talks will also explore 'innovative' pricing plans, such as linking payments for anti-obesity drugs to whether the treatment helps patients return to work. This comes as the US pharmaceutical industry increases pressure on the UK, with Keir Starmer agreeing to the first increase in NHS cost-effectiveness thresholds in 27 years. The threshold was raised from £20,000 to £30,000 a year for every year of life gained to £25,000 to £35,000.Eli Lilly was one of several pharmaceutical companies that ditched or paused almost £25bn in planned investments in the UK last year. The company paused its plans to invest in a laboratory site in central London. Jonsson stated that the resumption of Eli Lilly's investment would depend on the outcome of its talks with the government.He emphasized that prices for medicines in the UK had been 'far too low for far too long' and that the threshold couldn't remain static for another three decades. The UK agreed to pay 25% more for new medicines by 2035 as part of a US-UK drug pricing deal, which could eventually reach £9bn a year.Large pharmaceutical companies have protested about a 'rebate' scheme, under which they are required to pay back a chunk of revenue from sales of branded medicines. This scheme is expected to fall in 2026, although Jonsson believes payments 'should actually get down to zero' over time.